| INTRODUCTION

| Necrotizing soft tissue infections
Necrotizing soft tissue infections (NSTIs) are uncommon, severe, and potentially lethal conditions. 1, 2 Surviving often comes at the prize of life-lasting morbidity. 3 NSTI typically presents with pain, swelling, and skin discoloration 4 . The infection may involve any layer of soft tissue, causing local ischemia, tissue destruction, and necrosis. [4] [5] [6] Bacterial spread proceeds swiftly, frequently along fascial planes.
Host immunological response results in systemic toxicity. Shock, organ failure, and eventually death may result. [7] [8] [9] Microbiological findings frequently exhibit a distinguishing pattern with polymicrobial growth in samples from the pelvic region 10 ,11 † INFECT Study Group members are in Appendix 1.
and monomicrobial growth when a limb is affected. In the latter case, group A streptococcus is often found in cultures, but many other bacterial findings have been described as well. 4, [12] [13] [14] Mainstays of successful treatment are aggressive resuscitation, intravenous antibiotics, and prompt surgical resection of affected tissue. 4, 6, 8, 10, 12 Hyperbaric oxygen treatment (HBOT) is, by some, considered an adjuvant treatment resource. 8, 15, 16 Due to concurrent circulatory, respiratory, and renal disturbances, most patients are treated at intensive care units (ICU).
Diabetes is associated with an increased risk of infections 4, 17, 18 and is overrepresented among patients with NSTI, with a reported frequency of 20%-70%. 10, 11, 15, [19] [20] [21] [22] [23] In contrast, the World Health Organization (WHO) estimates global diabetes prevalence to be 8.5% in adults. 24 Concomitant diabetes seems to be a negative prognostic factor among patients with NSTI with increased risk of death, amputation, and infectious complications. 22, 23, [25] [26] [27] Hyperglycemia could be a factor associated with outcome in diabetic patients with NSTI. 
| Hypothesis
Our research hypothesis is that there are significant differences in both clinical characteristics, bacterial findings, and outcome among patients with NSTI and diabetes compared to patients with NSTI without diabetes.
| Study aim
The aim of this study is to report outcome for patients with NSTI
and diabetes compared to patients with NSTI without diabetes and to report clinical data for patients with NSTI and diabetes.
| ME TH ODS
| Study design
Prospective observational cohort study.
| Population
Adult (≥18 years) patients with NSTI.
| Exposure group
Patients with diabetes type 1 or type 2. 6. The presence of monomicrobial growth of group A streptococci (GAS) in cultures.
| Comparison group
Tissue and blood samples taken at referring hospital and study hospital are used. Tissue and blood samples taken at both referring hospital and study hospital are used. Tissue and blood samples taken at both referring hospital and study hospital are used. 
9.
The presence of polymicrobial flora in cultures.
Tissue and blood samples taken at both referring hospital and study hospital are used. RRT is defined as either intermittent hemodialysis or continuous renal replacement therapy.
| Exploratory outcomes
Comparisons are made within the group of patients with diabetes type 1 and type 2:
1. Association between glycated hemoglobin (A1C) values before admission and all-cause mortality 90 days after inclusion.
2.
All-cause mortality 90 days after inclusion in patients with diabetes type 1 compared to patients with diabetes type 2.
3. All-cause mortality 90 days after inclusion in patients with insulin-treated diabetes (type 1 and type 2) compared to non-insulintreated patients with diabetes type 2.
Association between A1C values before admission and days alive
and out of ICU at day 30 after inclusion.
5.
Association between A1C values before admission and the presence of polymicrobial flora in cultures.
Tissue and blood samples taken at both referring hospital and study hospital are used. INFECT is registered at ClinicalTrials.gov (NCT01790698).
| Study setting 2.9 | Inclusion criteria
Adult (≥18 years) patients with confirmed NSTI treated in one of the participating hospitals who consent to participate in the study.
The diagnosis of NSTI is made by the surgeon during the primary operation. It is based on, but not restricted to, findings of necrosis, dissolved or deliquescent soft tissue, and fascial and muscular affection.
| Exclusion criteria
Denial or withdrawal of consent.
Later refuted NSTI diagnosis.
| Subject enrollment
Patients are included by local research staff at each hospital. Consent is obtained according to national ethical regulations.
The research staff ensures that the consenting party is given oral and written information approved by the respective ethical committee about the nature, purpose, possible risk, and benefit of the study. 
| Timeline
The first patient was included in February 2013 and the last patient was included in June 2017. Patients' data registration is planned to be completed in March 2018.
| Data collection methods
Data are obtained from hospital medical records, hospital laboratories, and official death registries. Participation in the study results in additional blood sampling and extended collection of specimens for microbiological analysis.
| Registered variables
Description of clinical variables registered in the INFECT project including principles of bacterial categorization are available in a separate publication.
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Among patients with diagnosed diabetes, available A1C values from up to 6 months before inclusion are retrospectively collected from medical records.
Also in retrospect, patients with diabetes will be categorized as type 1, insulin-treated type 2, or non-insulin-treated type 2 based on information from medical records.
| Data management
All research data are handled confidentially and in accordance with national laws and regulations. Patients' data are anonymized, using an individual study code. Code lists are kept locked up and separate from registered study data. Original records will be retained at trial sites for the time specified by national regulations.
A common electronical database (eCRF) with all recorded data is kept in Copenhagen, Denmark (Danish Data protection Agency approval 30-0900). The trial database will be maintained for 15 years.
| Missing data
| Imputation
We will perform complete-case analyses. If the frequency of missing data for a given analysis is more than 5%, the analysis will be repeated using multiple imputation based on chained equations (MICE). The variables included in the multiple imputation will be age, SOFA score at day 1, the presence of hematological cancer, presence of diabetes, presence of chronic obstructive pulmonary disease (COPD) or asthma, presence of current or previous cardiovascular disease, presence of chronic kidney disease, GAS found in cultures and 90-day mortality. The variables used in specific analyses will be excluded from the imputation. We will also present unadjusted, non-imputed analyses.
| SAPS II score
If values from admission blood samples are missing, values from day 2 will be used.
| SOFA score
If values from blood samples at day 1 are missing, values from day 2 will be used. Due to the nature of eCRF, day 1 can vary from 0 to 24 hours. If day 1 is <12 hours, the worst value from either day 1 or day 2 is used. The SOFA score has been modified, as Glasgow Coma Scale (GCS) is not included.
| Diabetes type and A1C
If the amount of missing data exceeds 20%, the specific analysis will not be performed.
| STATISTICAL METHODS
| General analytical principles
For all analyses, the level of statistical significance (2-sided) is 0.05.
P-values will be adjusted for multiple testing by the Benjamini-Hochberg method.
| Outcomes
| Primary outcome
The primary outcome (all-cause mortality 90 days after inclusion) expressed as dichotomous variable (0-1) will be analyzed by logistic regression with 90 days mortality as response, having diabetes (dichotomous variable) as regressor and considering age (in years) as a covariate. Data will be presented as relative risks (RR) including 95% confidence intervals (CI).
| Secondary outcomes
The secondary outcomes will be analyzed by Fisher's exact test for categorical variables (amputation, affected body area, and renal replacement therapy) and by Mann-Whitney-Wilcoxon test for the continuous variables (SOFA score and SAPS II). Specific considerations are mentioned below.
Number of days alive and out of hospital at day 90 and days alive and out of ICU at day 30 will be analyzed by Mann-WhitneyWilcoxon test.
The presence of specific bacterial species in cultures of blood or tissue expressed as dichotomous variables (0-1) will be analyzed by logistic regression considering affected body area at admission as covariates. Data will be presented as RR including 95% CI.
| Exploratory outcomes
All-cause mortality at 90 days expressed as dichotomous variable (0-1) will be analyzed by logistic regression with mortality at 90 days as response and considering age (in years) as a covariate.
Regressors will be either dichotomous variables (diabetes subgroups: type 1 and type 2 or insulin-treated and non-insulin-trea- The presence of specific bacterial species in cultures of blood or tissue expressed as dichotomous variables (0-1) will be analyzed by logistic regression considering affected body area at admission as covariates. Data will be presented as RR including 95% CI.
| Clinical data, comorbidities, risk factors for NSTI, and medication
Data will be presented as number/total number (percentage), median (IQR), or mean (SD).
| Sample size estimation and sensitivity analysis
A total of 400 patients or more are expected to be included. Estimating a diabetes incidence between 25% and 35%, the group sizes will range between N 1 = 100 and 140 for the diabetics and N 2 = 300 and 260 for the nondiabetics.
Sensitivity analysis was performed with G*Power. The use of 4 arbitrarily defined body areas to describe the infectious locus makes data compilation and statistical analysis easier.
However, all categorization results in loss of information and reduced precision.
There is a relatively high number of secondary and exploratory outcomes. Statistical adjustment for multiple testing is used to reduce this risk of falsely positive findings. The amount of patients eligible for calculation of the exploratory outcomes will probably only number about 100-120, making statistical inference less precise.
Despite its limitations, this study will provide important data on patients with NSTI and diabetes.
ETHICS
The study is conducted in compliance with ICH Good Clinical Patients get no direct benefit from participation in the study.
Hopefully results from the study will lead to improved treatment for diabetic patients with NSTI in the future.
PUBLICATION
Results will be reported in accordance with STROBE guidelines for cohort studies 34 and submitted for publication in a peer-reviewed journal.
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